MDR Bacterial Infections Our Treatment Option

More documents

Recommendations

Info

January 2007 - December 2008,50 patients whom KPC-2–producing K. pneumoniae were isolated• Admitted in the ICU (n=34)• Colonized (n=32)• Infected ( n=18)38 patients (76%) were identified after August 2008• Bacteremia 14• Surgical site infections 2• Lower respiratory tract infections 2 (1 bacteremic)• UTI 1Most patients received a colistin-containing combination Rx.Crude mortality Attributable mortality• Among ICU patients 58.8% 22.2%• Among non-ICU patients 37.5% 33.3%Maria Souli, Irene Galani, Anastasia Antoniadou. An Outbreak of Infection due to b-Lactamase Klebsiella pneumoniae Carbapenemase 2–Producing K. pneumoniae in a Greek University Hospital: Molecular Characterization, Epidemiology, and Outcomes. Clinical InfectiousDiseases 2010; 50:364–73.
KPC-p K. pneumoniaeisolate. (USA)Carbapenem-resistantK. pneumoniae due to- porin-loss- CTX-M-15 ESBL production- cephalosporinase hyperproductionModifiedHodge Testscreening test forcarbapenemaseproducingbacteria.KPC-p K. pneumoniaeisolate. (Greece)imipenem diskWild-type K. pneumoniaeisolateCarbapenemase GES-5-p E. cloacaeF = E coli DH10Bas lawn bacteriaKPCscreeningA susceptibleisolate of E. coliDH10B iscultured on aMueller-Hintonplate to create alawn of confluentgrowth
Page 1 and 2: MDR Bacterial Infections:Our Treatm
Page 5 and 6: IDSA News: 10 New Antibiotics by 20
Page 7 and 8: 60504030201001911102010719992000261
Page 9 and 10: Definition & Action of KPC, CRKP an
Page 11 and 12: Maria Souli, Irene Galani, Anastasi
Page 13: Antimicrobial Susceptibility for ND
Page 18 and 19: MIC distributions of NDM-1 Enteroba
Page 20 and 21: Drug of Choice for ESBL-producingEn
Page 22 and 23: Antimicrobial Option by Risk Level
Page 24 and 25: In vitro activities of fosfomycin a
Page 26 and 27: 0.5, 1.0, 2.0-gm Human Simulated Pr
Page 28 and 29: FIC Index & InterpretationInterpret
Page 30 and 31: FIC Index of MDR P. aeruginosaStrai
Page 32 and 33: Population PharmacokineticAnalysis
Page 34 and 35: Attenuation of Colistin Bactericida
Page 36 and 37: Pharmacokinetic/Pharmacodynamic Det
Page 38 and 39: Recommended Definite Therapy for Se
Page 40 and 41: Breakpoint Criteria of Vancomycin f
Page 42 and 43: One Gram bid: Enough for Vancomycin
Page 44 and 45: การใชยา vancomycin
Page 46 and 47: ยาขนานอื่น ถ
Page 48 and 49: Early Combination Rx vs. Monotherap
Page 54: Thank youAny Comment?Any Question?

MDR Bacterial Infections Our Treatment Option

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?